摘要
目的了解淮南地区临床分离鲍曼不动杆菌对临床常用抗生素的耐药性，指导临床合理使用抗生素。方法选择淮南地区3家医院2010年10月至2012年6月临床分离鲍曼不动杆菌160株，应用生物梅里埃公司的VITEK32全自动微生物分析系统进行细菌鉴定和药物敏感试验，头孢哌酮／舒巴坦药敏试验使用纸片扩散法检测。结果鲍曼不动杆菌对10种抗菌药物耐药率高于50．0％，其中对氨曲南的耐药率达到90．1％；仅对4种抗菌药物耐药率低于50．0％，其中对头孢哌酮／舒巴坦耐药率最低，为23．4％，其次为亚胺培南和美罗培南，耐药率分别为26．0％和31．2％。结论淮南地区临床分离的鲍曼不动杆菌耐药和多重耐药现象严重，头孢哌酮／舒巴坦和亚胺培南可做为临床鲍曼不动杆菌感染治疗的首选药物。
Objective To investigate the antimicrobial resistance of clinical isolated acinetobacter baumannii against the common antimicrobial agents in Huainan and to direct rational medication in clinical. Methods 160 acinetobacter baumannii strains were isolated from 3 hospitals in Huainan from Oct. 2010 to Jun. 2012. Bacteria identification and antimicrobial susceptibility testing were detected by VITEK32 of BioM6rieux company. Cefoperazone sulbactam susceptibility was detected by Kirby-Bauer method. Results The drug resistant rate of acinetobacter bau- mannii against 10 antimicrobial agents was beyond 50.0% and resistant rate of aztreonam was up to 90.1%. The drug resistant rate of only 4 antimicrobial agents was lower than 50.0%. In these 4 drugs, the lowest drug resistant rate was cefoperazone sulbactam （23.4%） and antimicrobial resistant rate of imipenem and meropenem was 26.0% and 31.2% ,respectively. Conclusion The antibiotic resistance and multiple resistance of acinetobacter baumannii in Huainan is serious. Cefoperazone sulbactam and imipenem are the first drugs for clinical therapy of aeinetobacter baumannii infection.
出处
《中国基层医药》
CAS
2013年第22期3364-3365,共2页
Chinese Journal of Primary Medicine and Pharmacy
基金
安徽省淮南市科技局科技项目（2010A0601102）
关键词
鲍曼不动杆菌
抗菌药物
耐药性
Acinetobacter baumannii
Antimicrobial agent
Antimicrobial resistance
